Compare ZTO & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZTO | RVPH |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 71.0M |
| IPO Year | 2016 | N/A |
| Metric | ZTO | RVPH |
|---|---|---|
| Price | $21.46 | $0.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.90 | $3.33 |
| AVG Volume (30 Days) | 1.6M | ★ 4.3M |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $6,673,175,085.00 | N/A |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $11.36 | N/A |
| P/E Ratio | $18.48 | ★ N/A |
| Revenue Growth | ★ 13.17 | N/A |
| 52 Week Low | $16.34 | $0.25 |
| 52 Week High | $22.01 | $2.95 |
| Indicator | ZTO | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 67.89 | 58.18 |
| Support Level | $20.71 | $0.60 |
| Resistance Level | $21.88 | $0.77 |
| Average True Range (ATR) | 0.39 | 0.05 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 84.15 | 61.01 |
ZTO Express is China's largest express delivery company by parcel volume, with a volume share of 19.4% in 2024. It operates a network partner model where it provides line-haul transportation and sorting services, while its local network partners provide first-mile pickup and last-mile delivery services under the ZTO brand name. Headquartered in Shanghai, the company was founded in 2002 by Meisong Lai, who remains chair, CEO, and its major shareholder with 78% voting rights as of March 31, 2025. ZTO's strategic shareholder is leading China e-commerce company Alibaba Group with around an 8.9% interest.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.